Release time：Oct 13, 2021
On October 11, during the International Biopharma Industry Week Shanghai 2021, the 2021 Shanghai (Minhang) Biopharma Industry Innovation Summit was held, at the special dinner awards ceremony, the list of award-winning enterprises in the 3rd BIGStar of 2021, jointly selected by eMedClub-BIGStar Institute and experts from the industry, was officially announced. Mabwell was awarded the BIGStar 2021 Chinese Most Promising Innovative Biopharmaceutical Enterprises.
The award is a full affirmation by industry experts and media of Mabwell's independent innovation and development capabilities. As an innovation-driven biopharmaceutical company Mabwell Bioscience has whole industrial chain of R&D, manufacturing, and commercialization. It is committed to fulfill clinical needs through original innovation capability and focusing on breakthroughs in critical technology fields.
Innovation is the driving force of new drug research and development. Mabwell’s vision is “Innovation, from ideas to reality”. And we will continue to move forward and innovate, providing patients with more effective and accessible therapy and innovative medicines to fulfill global medical needs.
